GlassScriptPhysician profile
Jill M Mazza
NPI 1700049731
$4,206.53
in general payments reported to CMS, 2019-2025
19 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $395 · 2021: $777 · 2022: $815 · 2023: $641 · 2024: $424 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $791.47 | 2019-2025 | |
| Optinose US, INC. | $627.95 | 2019-2025 | |
| Acclarent, INC | $474.63 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $404.58 | 2019-2024 | Dupixent |
| Glaxosmithkline, LLC. | $340.33 | 2021-2025 | Nucala |
| Abiomed | $330.85 | 2019 | |
| Stryker Corporation | $299.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $193.19 | 2021-2023 | |
| Aerin Medical INC. | $161.35 | 2019-2021 | |
| Medtronic, INC. | $110.65 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $102.01 | 2020-2023 | Fasenra |
| Hikma Pharmaceuticals USA | $98.95 | 2023-2025 | Ryaltris |
| Sanofi-Aventis U.S. LLC | $81.26 | 2019-2022 | |
| Gilead Sciences, INC. | $75.34 | 2020 | |
| Phadia US INC. | $35.72 | 2023-2024 | Immunocap |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $24.25 | 2025 | Inspire |
| Alk-Abello, INC | $23.22 | 2019 | |
| Integra Lifesciences Corporation | $17.72 | 2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Intersect Ent, INC. | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Mazza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.